Héctor F Escobar-Morreale1, M Belén Roldán-Martín2. 1. Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology & Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria, CIBERDEM, Madrid, Spain hectorfrancisco.escobar@salud.madrid.org. 2. Department of Pediatrics, Hospital Universitario Ramón y Cajal and Universidad de Alcalá, Madrid, Spain.
Abstract
BACKGROUND: A few small studies have reported increased prevalences of polycystic ovary syndrome (PCOS) and symptoms of androgen excess in women with type 1 diabetes. PURPOSE: We performed a systematic review and meta-analysis of studies evaluating androgen excess symptoms and PCOS in women with type 1 diabetes. DATA SOURCES: The Entrez-PubMed and Scopus electronic databases were used. STUDY SELECTION: We selected studies addressing androgen excess signs, symptoms, and disorders in girls, adolescents, and adult women with type 1 diabetes. DATA EXTRACTION: The main outcome measures were prevalences of PCOS, hyperandrogenemia, hirsutism, menstrual dysfunction, and polycystic ovarian morphology (PCOM). DATA SYNTHESIS: Nine primary studies involving 475 adolescent or adult women with type 1 diabetes were included. The prevalences of PCOS and associated traits in women with type 1 diabetes were 24% (95% CI 15-34) for PCOS, 25% (95% CI 17-33) for hyperandrogenemia, 25% (95% CI 16-36) for hirsutism, 24% (95% CI 17-32) for menstrual dysfunction, and 33% (95% CI 24-44) for PCOM. These figures are considerably higher than those reported earlier in the general population without diabetes. LIMITATIONS: The data collected in the original studies were heterogeneous in age, race, ethnicity, and criteria used for the diagnosis of PCOS; yet, we used a quality-effects model in the meta-analyses to overcome this limitation. CONCLUSIONS: PCOS and its related traits are frequent findings in women with type 1 diabetes. PCOS may contribute to the subfertility of these women by a mechanism that does not directly depend on glycemic/metabolic control among other negative consequences for their health. Hence, screening for PCOS and androgen excess should be included in current guidelines for the management of type 1 diabetes in women.
BACKGROUND: A few small studies have reported increased prevalences of polycystic ovary syndrome (PCOS) and symptoms of androgen excess in women with type 1 diabetes. PURPOSE: We performed a systematic review and meta-analysis of studies evaluating androgen excess symptoms and PCOS in women with type 1 diabetes. DATA SOURCES: The Entrez-PubMed and Scopus electronic databases were used. STUDY SELECTION: We selected studies addressing androgen excess signs, symptoms, and disorders in girls, adolescents, and adult women with type 1 diabetes. DATA EXTRACTION: The main outcome measures were prevalences of PCOS, hyperandrogenemia, hirsutism, menstrual dysfunction, and polycystic ovarian morphology (PCOM). DATA SYNTHESIS: Nine primary studies involving 475 adolescent or adult women with type 1 diabetes were included. The prevalences of PCOS and associated traits in women with type 1 diabetes were 24% (95% CI 15-34) for PCOS, 25% (95% CI 17-33) for hyperandrogenemia, 25% (95% CI 16-36) for hirsutism, 24% (95% CI 17-32) for menstrual dysfunction, and 33% (95% CI 24-44) for PCOM. These figures are considerably higher than those reported earlier in the general population without diabetes. LIMITATIONS: The data collected in the original studies were heterogeneous in age, race, ethnicity, and criteria used for the diagnosis of PCOS; yet, we used a quality-effects model in the meta-analyses to overcome this limitation. CONCLUSIONS:PCOS and its related traits are frequent findings in women with type 1 diabetes. PCOS may contribute to the subfertility of these women by a mechanism that does not directly depend on glycemic/metabolic control among other negative consequences for their health. Hence, screening for PCOS and androgen excess should be included in current guidelines for the management of type 1 diabetes in women.
Authors: C Kim; R S Miller; B H Braffett; Y Pan; V L Arends; A K Saenger; A Barnie; A V Sarma Journal: Clin Endocrinol (Oxf) Date: 2018-01-26 Impact factor: 3.478
Authors: Catherine Kim; Carrie Karvonen-Gutierrez; Shengchun Kong; Valerie Arends; Michael Steffes; Daniel S McConnell; John F Randolph; Siobán D Harlow Journal: Fertil Steril Date: 2016-07-28 Impact factor: 7.329
Authors: William T Cefalu; Andrew J M Boulton; William V Tamborlane; Robert G Moses; Derek LeRoith; Eddie L Greene; Frank B Hu; George Bakris; Judith Wylie-Rosett; Julio Rosenstock; Steven E Kahn; Katie Weinger; Lawrence Blonde; Mary de Groot; Stephen Rich; David D'Alessio; Lyn Reynolds; Matthew C Riddle Journal: Diabetes Care Date: 2017-01 Impact factor: 19.112
Authors: Catherine Kim; Yuanyuan Pan; Barbara H Braffett; Valerie L Arends; Michael W Steffes; Hunter Wessells; Aruna V Sarma Journal: Womens Midlife Health Date: 2017-08-18
Authors: Ramon Bossardi Ramos; Lucas Bandeira Marchesan; Poli Mara Spritzer; Monica de Oliveira; Enrico Carmina Journal: Diabetol Metab Syndr Date: 2021-02-16 Impact factor: 3.320